InVivoMAb anti-Dengue virus type 2 E protein DIII

Georgiev GI, Malonis RJ, Wirchnianski AS, et al. Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses in vivo. Cell Chem Biol. 2022,29(5):811-823.e7. doi: 10.1016/j.chembiol.2022.02.004

Rockstroh A, Barzon L, Pacenti M, et al. Recombinant Envelope-Proteins with Mutations in the Conserved Fusion Loop Allow Specific Serological Diagnosis of Dengue-Infections. PLoS Negl Trop Dis. 2015,9(11):e0004218. doi: 10.1371/journal.pntd.0004218

De Burghgraeve T, Kaptein SJ, Ayala-Nunez NV, et al. An analogue of the antibiotic teicoplanin prevents flavivirus entry in vitro. PLoS One. 2012,7(5):e37244. doi: 10.1371/journal.pone.0037244

da Silva Voorham JM, Rodenhuis-Zybert IA, Ayala Nuñez NV, et al. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2. PLoS One. 2012,7(3):e29957. doi: 10.1371/journal.pone.0029957

Sukupolvi-Petty S, Austin SK, Engle M, et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol. 2010,84(18):9227-39. doi: 10.1128/JVI.01087-10